Cyclosporine A

Calcineurin inhibitor; suppresses T-cell activation and cytokine production

Response rate
Variable
Onset
Days to weeks
Route
Oral 2-5 mg/kg/day
Line
Alternative
IgM effect
No direct effect

Evidence summary

Particularly valuable in the treatment of AOSD-associated macrophage activation syndrome (MAS), where it helps control the hyperinflammatory state by suppressing T-cell and macrophage activation. Also used as a steroid-sparing agent in refractory systemic disease. Requires monitoring of renal function and blood pressure. Often combined with corticosteroids for MAS management.

Sources (3)

DetailsRuscitti P et al. (2017) Macrophage activation syndrome in patients affected by adult-onset Still disease: analysis of survival rate and its causes of death · MedicinePubMed
DetailsEfthimiou P et al. (2018) Complications of adult-onset Still's disease and their management · Expert Rev Clin ImmunolPubMed
DetailsJamilloux Y et al. (2015) Treatment of adult-onset Still's disease: a review · Ther Clin Risk ManagPubMed